Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
Azusa Tanimoto(The University of Texas MD Anderson Cancer Center), Seiji Yano(Kanazawa University Hospital)
Cited by 53
Related Papers
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|174
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
|Nature Communications|2020|112